It is used for the control of infestations caused by gastrointestinal, pulmonary, cutaneous and gastrophilic parasites: Strongylus vulgaris, edentatus and equinus. Trichostrongylus axi., Strongyloides westeri., Oxyuris equi., Parascaris equorum. , Gasterophilus spp., Rhinoestrus purpureus., Draschia megastoma.

PYRAKO ORAL PASTE, a premium product from VEKO, is an essential dewormer in the veterinary medicine category, specifically formulated for horses. Containing the active ingredient Pyrantel Pamoate, this paste is effective against a range of parasitic infections. Committed to animal health, Animeal is proud to offer PYRAKO ORAL PASTE, ensuring the well-being of horses with trusted and effective solutions. Ingredients: Pyrantel Pamoate (11.41 gm): As the main active ingredient, Pyrantel Pamoate is a tetrahydropyrimidine compound highly effective against gastrointestinal nematodes like roundworms. It acts as a depolarizing neuromuscular blocking agent, paralyzing parasites and facilitating their expulsion from the host's system​​​​​​​​​​.

Savavet Kiwof Plus Dog Deworming Tablet is a broad-spectrum dewormer for dogs. It is effective against a wide range of intestinal parasites, including roundworms, hookworms, whipworms, and tapeworms. Kiwof Plus is safe for use in puppies and adult dogs. Here are some of the benefits of using Savavet Kiwof Plus Dog Deworming Tablet: It is effective against a wide range of intestinal parasites. It is safe for use in puppies and adult dogs. It is easy to administer. It is available in a chewable tablet form.

Zoetis Simparica Trio chewable tablets offer advanced, all-in-one protection against ticks, fleas, heartworms, and intestinal worms in dogs. Each tablet includes three potent active substances that provide broad-spectrum parasite control to keep your pet healthy and free of parasites. Designed for dogs of all sizes, this chewable flea and tick treatment is very appetizing, making administration simple. The pack of three tablets provides three months of continuous protection, providing pet owners with a convenient option for flea, tick, and worm prevention. Simparica Trio for dogs provides long-lasting, efficient protection against dangerous parasites. Composition: SAROLANER + MOXIDECTIN + PYRANTEL Class: Anti-tick & flea tablet

Overview: PANACUR POWDER, containing the active ingredient Fenbendazole, stands as a cornerstone in animal healthcare. It's a broad-spectrum dewormer, effectively combating gastrointestinal parasites like giardia, roundworms, hookworms, whipworms, and tapeworms. Animeal takes pride in offering this highly tolerable and low-toxicity medication, suitable for a range of animals including cattle, sheep, goats, and pigs​​​​. Ingredients: Fenbendazole (250 mg per gram): The main ingredient, Fenbendazole, is a potent anthelmintic. It's minimally absorbed from the gastrointestinal tract, ensuring its targeted action against parasites. It's also metabolized into oxfendazole, contributing to its efficacy​​​​.

Virbac Ipraz Dewormer Tablets for Dogs is a broad-spectrum deworming medication designed to eliminate and control internal parasites in dogs. It is formulated with a combination of antiparasitic agents, including ivermectin and praziquantel, which work together to target a wide range of worms commonly found in dogs. Composition: IVERMECTIN + PRAZIQUANTEL Class: Dewormer Uses of medicine Treats tapeworm infestation and prevents it from happening again It controls and eliminates the roundworm infection in the digestive tract It can act as a comprehensive protection against all intestinal worms.

enbendazole is a benzimidazole that presents a wide spectrum anthelmintic effect. It is used against a number of gastrointestinal parasites including giardia, roundworms, hookworms, whipworms, the Taenia genus of tapeworms, pinworms, aelurostrongylus, paragonimiasis, strongyles, and Strongyloides.

ivermectin for humans 12mg Tablet ₹ 50 / Stripe Get Latest Price Strength 12mg Packaging Type Strip Prescription Required Yes Composition (Salts) Ivermectin Usages Covid 19 Although vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), have been developed and distributed, major challenges remain regarding vaccine production and allocation.1 The identification of inexpensive, widely available, and effective therapies against Covid-19 is of great importance. The repurposing of existing medicines that are widely available and that have reasonably well understood safety profiles has appeal.2 One drug that has received considerable public use and interest is ivermectin, which is typically used as an antiparasitic drug. Ivermectin inhibits the chloride channels of helminthic parasites and has been shown to have clinical efficacy for the treatment of onchocerciasis, strongyloidiasis, and ectoparasitic infection (e.g., scabies).3 The in vitro antiviral activity of ivermectin has been explored against a spectrum of viruses, including severe acute respiratory syndrome coronavirus 1, human immunodeficiency virus, dengue virus, Zika virus, yellow fever virus, West Nile virus, Hendra virus, chikungunya virus, Semliki Forest virus, Sindbis virus, and avian influenza virus.4 More than 60 randomized trials of ivermectin for the treatment of Covid-19 have been registered, and findings have been reported for as many as 31 clinical trials.5 The results have been discordant, and various review groups interpret the evidence differently — some advocating for benefits of ivermectin, and others reticent to conclude a benefit.6-8 However, most trials have been small, and several have been withdrawn from publication owing to concerns about credibility.9 To evaluate the efficacy of ivermectin for the prevention of progression of Covid-19 resulting in hospitalization among outpatients with SARS-CoV-2 infection, we conducted a randomized, placebo-controlled, adaptive platform trial (TOGETHER) in the state of Minas Gerais, Brazil. Although various interventions were assessed in this trial, we report here on the use of ivermectin at a dose of 400 μg per kilogram of body weight for 3 days as compared with placebo.

iveremectin Ivecop 6 Mg Tablet ₹ 35 / Stripe Get Latest Price Strength 6mg Packaging Type Strip Prescription Required Yes Composition (Salts) Ivermectin Usages Covid 19 Although vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), have been developed and distributed, major challenges remain regarding vaccine production and allocation.1 The identification of inexpensive, widely available, and effective therapies against Covid-19 is of great importance. The repurposing of existing medicines that are widely available and that have reasonably well understood safety profiles has appeal.2 One drug that has received considerable public use and interest is ivermectin, which is typically used as an antiparasitic drug. Ivermectin inhibits the chloride channels of helminthic parasites and has been shown to have clinical efficacy for the treatment of onchocerciasis, strongyloidiasis, and ectoparasitic infection (e.g., scabies).3 The in vitro antiviral activity of ivermectin has been explored against a spectrum of viruses, including severe acute respiratory syndrome coronavirus 1, human immunodeficiency virus, dengue virus, Zika virus, yellow fever virus, West Nile virus, Hendra virus, chikungunya virus, Semliki Forest virus, Sindbis virus, and avian influenza virus.4 More than 60 randomized trials of ivermectin for the treatment of Covid-19 have been registered, and findings have been reported for as many as 31 clinical trials.5 The results have been discordant, and various review groups interpret the evidence differently — some advocating for benefits of ivermectin, and others reticent to conclude a benefit.6-8 However, most trials have been small, and several have been withdrawn from publication owing to concerns about credibility.9 To evaluate the efficacy of ivermectin for the prevention of progression of Covid-19 resulting in hospitalization among outpatients with SARS-CoV-2 infection, we conducted a randomized, placebo-controlled, adaptive platform trial (TOGETHER) in the state of Minas Gerais, Brazil. Although various interventions were assessed in this trial, we report here on the use of ivermectin at a dose of 400 μg per kilogram of body weight for 3 days as compared with placebo.